Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. TPST, AFMD, ANEB, IXHL, FGEN, VRCA, MDCX, IRD, RAPT, and OKUR

Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Tempest Therapeutics (TPST), Affimed (AFMD), Anebulo Pharmaceuticals (ANEB), Incannex Healthcare (IXHL), FibroGen (FGEN), Verrica Pharmaceuticals (VRCA), Medicus Pharma (MDCX), Opus Genetics (IRD), RAPT Therapeutics (RAPT), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical preparations" industry.

XTL Biopharmaceuticals vs.

Tempest Therapeutics (NASDAQ:TPST) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tempest TherapeuticsN/A -187.44% -82.61%
XTL Biopharmaceuticals N/A N/A N/A

Tempest Therapeutics received 21 more outperform votes than XTL Biopharmaceuticals when rated by MarketBeat users. However, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote.

CompanyUnderperformOutperform
Tempest TherapeuticsOutperform Votes
100
65.79%
Underperform Votes
52
34.21%
XTL BiopharmaceuticalsOutperform Votes
79
71.82%
Underperform Votes
31
28.18%

Tempest Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 2,762.87%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempest Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
XTL Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempest TherapeuticsN/AN/A-$29.49M-$1.53-0.46
XTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/A

Tempest Therapeutics has a beta of -1.78, indicating that its share price is 278% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

In the previous week, Tempest Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 1 mentions for Tempest Therapeutics and 0 mentions for XTL Biopharmaceuticals. Tempest Therapeutics' average media sentiment score of 0.38 beat XTL Biopharmaceuticals' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Tempest Therapeutics Neutral
XTL Biopharmaceuticals Neutral

Summary

Tempest Therapeutics beats XTL Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XTLB vs. The Competition

MetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.14M$6.71B$5.03B$8.97B
Dividend YieldN/A3.07%4.81%4.06%
P/E RatioN/A10.45133.1816.92
Price / SalesN/A187.361,119.91116.20
Price / CashN/A57.1640.6337.94
Price / Book3.645.194.754.71
Net Income-$1.78M$151.85M$118.34M$225.20M

XTL Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XTLB
XTL Biopharmaceuticals
N/A$1.49
-4.5%
N/A+59.7%$8.14MN/A0.00N/A
TPST
Tempest Therapeutics
1.8676 of 5 stars
$0.80
flat
$20.00
+2,400.0%
-83.1%$34.91MN/A-0.5320
AFMD
Affimed
4.4145 of 5 stars
$2.13
-0.9%
$13.50
+533.8%
-68.5%$34.29M$8.95M0.0076News Coverage
Gap Down
ANEB
Anebulo Pharmaceuticals
2.4175 of 5 stars
$1.30
-7.1%
$8.00
+515.4%
-40.0%$33.71MN/A-4.674Gap Up
High Trading Volume
IXHL
Incannex Healthcare
0.1672 of 5 stars
$1.90
+2.2%
N/A-46.1%$33.52M$86,000.00-1.343
FGEN
FibroGen
2.5101 of 5 stars
$0.33
-3.0%
N/A-46.1%$32.76M$180.02M-0.28486Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
VRCA
Verrica Pharmaceuticals
4.6721 of 5 stars
$0.72
-5.6%
$9.50
+1,223.1%
-88.4%$32.74M$5.12M-0.4040
MDCX
Medicus Pharma
N/A$2.95
+7.3%
N/AN/A$32.00MN/A0.00N/AAnalyst Forecast
IRD
Opus Genetics
2.714 of 5 stars
$1.00
-2.0%
$8.00
+700.0%
N/A$31.57M$8.38M-0.92N/AHigh Trading Volume
RAPT
RAPT Therapeutics
4.6878 of 5 stars
$0.88
-3.2%
$9.50
+978.0%
-95.9%$30.81M$1.53M-0.3380
OKUR
OnKure Therapeutics
3.9426 of 5 stars
$9.08
-7.9%
$36.00
+296.5%
N/A$30.33MN/A-0.81N/AHigh Trading Volume

Related Companies and Tools


This page (NASDAQ:XTLB) was last updated on 12/19/2024 by MarketBeat.com Staff
From Our Partners